R.I. Hospital needs recruits for Alzheimer's clinical trial

R.I. Hospital needs recruits for Alzheimer's clinical trial

PROVIDENCE - Rhode Island Hospital is recruiting participants for a national clinical trial to test a new investigational drug intervention that may reduce the risk and development of Alzheimer's disease.

The anti-amyloid treatment in asymptomatic Alzheimer's disease trial is for individuals ages 65-85 who may be at risk for memory loss due to Alzheimer's disease. It will test a new investigational drug.

The goal is to slow possible Alzheimer's-related damage in the brain and to delay symptoms of memory loss. The investigational drug, which binds to amyloid proteins, is expected to slow decline in memory and thinking as measured by cognitive tests, if treatment is started before there is evidence of Alzheimer's-related symptoms and brain injury.

Each participant is required to undergo a PETscan to measure amyloid in the brain. Participants with normal thinking and memory abilities, an elevated amyloid level and who pass screening evaluations of their general health, will be randomly assigned to receive either the investigative antibody drug or a placebo. The drug and placebo are given by an intravenous infusion every four weeks. Participants will be monitored for the duration of the trial.

For more information or to find out if you qualify, contact Kerstin Calia at 401-444-9861 or kcalia@lifespan.org.